证券日报网讯新和成11月24日发布公告，在公司回答调研者提问时表示，公司年产45吨全氟己基辛烷、 15吨全氟丁基戊烷项目已具备生产能力，两款产品是治疗干眼症药物的重要原料药，已取得药品注册。 （文章来源：证券日报） ...

Group 1: Company Overview - The company is Zhejiang Xinhacheng Co., Ltd., with stock code 002001 and abbreviation Xinhacheng [1] - The investor relations activity was recorded under number 2025-014 [1] Group 2: Investor Relations Activity - The activity included a strategy meeting with various investment firms and analysts [2] - Key participants included representatives from Guosen Securities, Qianhai Hezhi, and Huaxia Fund among others [2] Group 3: Project Updates - The Tianjin Nylon New Materials project commenced pile foundation construction in September 2025 and is expected to be completed by 2027 [3] - The company has a solid methionine production capacity of 30,000 tons, with an expansion project of 70,000 tons nearing completion [3] - The Heilongjiang base focuses on bio-fermentation products, including Vitamin C and various amino acids, enhancing overall efficiency through technological upgrades [3] Group 4: New Materials and Product Development - The company aims to be a leader in the new materials sector, focusing on high-performance polymers like PPS, with a current capacity of 22,000 tons and plans for expansion [4] - The fragrance segment produces various products, including linalool and citral, with ongoing projects to enhance product offerings [4] Group 5: Future Plans and Strategic Focus - The company plans to focus on health and high polymer new materials, emphasizing integrated and collaborative development strategies [6] - A share buyback plan is in place, with a total amount of 300 million to 600 million yuan allocated for stock repurchase to enhance investor confidence [6]

Group 1 - The company has established production capabilities for perfluorohexane and perfluorobutylpentane, with an annual output of 45 tons and 15 tons respectively [2] - Both products are important raw materials for the treatment of dry eye disease and have obtained drug registration [2] - The company is responding to investor inquiries regarding the market potential and exclusivity of these products [2]